Serum and Plasma Copy Number Detection Using Real-time PCR
December 15th, 2017
This manuscript describes the copy number variation analysis performed in serum or plasma DNA using real-time PCR approach. This method is suitable for the prediction of drug resistance in castration resistant prostate cancer patients, but it could be informative also for other diseases.
The overall goal of this method is to detect the gene copy number variation in serum or plasma samples.This method can help answer key questions in advanced prostate cancer field such as detection of markers useful to predict or monitor the spores reduction.The main advantage of this technique is that it is easy and fast to do.The implications of this technique extend toward therapy of advanced prostate cancer because androgen receptor gene copy number variation is a frequent event.Generally, individuals new to this method will struggle because the concentration and the quality of cell-free DNA is often lower than expected.For serum collection, work from five milliliter samples of whole blood and serum without anticoagulants maintained at four degrees Celsius.Start by centrifuging the samples for 15 minutes at 1, 000 g.The supernatant is the serum.Transfer it into two-milliliter tubes and discard the pellet.Unless the serum is processed immediately, freeze the samples at 80
View the full transcript and gain access to thousands of scientific videos
Overview
This manuscript describes the copy number variation analysis performed in serum or plasma DNA using a real-time PCR approach. This method is suitable for predicting drug resistance in castration-resistant prostate cancer patients and could be informative for other diseases.
Key Study Components
Area of Science
- Oncology
- Genomics
- Clinical Research
Background
- Copy number variation (CNV) can influence disease progression.
- Real-time PCR is a sensitive method for detecting CNVs.
- Castration-resistant prostate cancer presents unique challenges in treatment.
- Understanding drug resistance mechanisms is critical for patient management.
Purpose of Study
- To analyze CNV in serum or plasma DNA.
- To assess the potential of this method in predicting drug resistance.
- To explore its applicability to other diseases.
Methods Used
- Real-time PCR for CNV analysis.
- Sample collection from serum or plasma.
- Statistical analysis of CNV data.
- Comparison with clinical outcomes in prostate cancer patients.
Main Results
- Identification of specific CNVs associated with drug resistance.
- Correlation between CNV patterns and patient outcomes.
- Demonstration of the method's sensitivity and specificity.
- Potential implications for treatment strategies in prostate cancer.
Conclusions
- The real-time PCR method is effective for CNV analysis.
- Findings may enhance understanding of drug resistance in cancer.
- Further research is needed to validate findings in other diseases.
Frequently Asked Questions
Executive Industry Relevance
Detection of androgen receptor copy number gain in circulating cell-free DNA enables non-invasive monitoring of therapeutic resistance mechanisms in metastatic castration-resistant prostate cancer. This approach supports early identification of treatment failure and informs clinical decision-making through minimally invasive sampling. The method provides a rapid, scalable workflow for biomarker assessment in liquid biopsy applications.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of AR gene amplification as a driver of therapeutic resistance in prostate cancer models.
- Operational Value: Uses cfDNA from serum/plasma to avoid invasive tissue sampling in longitudinal studies.
Screening & Assay Development
- Scientific Value: Delivers quantitative CN measurements using duplex real-time PCR with RNaseP and AGO1 reference genes.
- Operational Value: Standardized input of 60 ng DNA per assay ensures reproducibility across sample sets.
Translational & Preclinical Research
- Scientific Value: cfDNA AR CN gain correlates with progression in mCRPC, supporting biomarker qualification efforts.
- Operational Value: Non-invasive sample collection enables frequent monitoring in preclinical and clinical cohorts.
Pipeline & Workflow Integration
The method fits within the biomarker discovery continuum, supporting target validation through liquid biopsy and enabling downstream screening of resistance mechanisms in prostate cancer models.
- Discovery Biology: Tests hypothesis that AR CN gain in cfDNA predicts treatment resistance in advanced prostate cancer.
- Screening: Generates quantitative CN data suitable for assay standardization and compound effect evaluation.
- Analytics: Provides CNV ratios relative to reference genes for statistical comparison across conditions.
- Translational Research: Links cfDNA biomarkers to clinical outcomes in castration-resistant prostate cancer.
- Enterprise Reuse: Workflow adapts to other gene targets and disease settings beyond prostate cancer.
Operational & Enterprise Impact
- Scientific Value: Mechanistic de-risking of AR amplification as a resistance biomarker in prostate cancer.
- Operational Value: Rapid, low-input protocol using standard real-time PCR equipment.
- Strategic Value: Enables go/no-go decisions based on non-invasive resistance monitoring.
- Portfolio Impact: Supports risk-adjusted prioritization of therapies targeting AR pathway alterations.
Implementation Considerations
- Requires expertise in cfDNA extraction and quantification from low-yield samples.
- Dependent on real-time PCR instrumentation with multiplexing capability.
- Needs standardization across laboratories for reference gene selection and data analysis.
- Limited by cfDNA quantity and quality, necessitating input optimization.
- Validation with orthogonal methods like digital PCR recommended for CN gain confirmation.
Biopharma FAQs
Chapters in this video
0:05
Title
0:55
Collection of Serum or Plasma
2:20
Isolating Cell-free (cfDNA) from Serum or Plasma
5:15
Real-time PCR and Analysis of cfDNA
7:36
Results: Detection of Androgen Receptor (AR) Copy Number Variations in cfDNA of Metastatic Castration-resistant Prostate Cancer (CRPC) Patients
8:25
Conclusion
